Brain Cancer


Glioblastoma multiforme (GBM) is the most common and aggressive of all primary brain cancer diagnosed in adults.

Worldwide in 2020, almost 300,00 people were diagnosed for the first time with brain cancer and in the same year 250,000 people died from their disease. Glioblastoma multiforme (GBM) is the most common and aggressive primary brain cancer diagnosed in adults, accounting for more than half of all brain cancers. The outlook for people diagnosed with GBM is poor, with half of all patients surviving between 12-18 months, 25% for more than 12 months, and only 5% surviving for five years. Telix’s brain cancer clinical program is focused on treatment with its TLX101 therapeutic candidate.




About TLX101

TLX101 (4-iodo-[131I]-phenylalanine or 131I-IPA) is a new investigational therapeutic radiopharmaceutical being developed to treat glioblastoma (GBM). TLX101 targets LAT-1, a promising target in several cancer types, including glioblastoma. TLX101 is a novel approach that is readily able to pass through the blood-brain barrier, the normal protective barrier that prevents many potential drug candidates from entering the brain.


Current development activity

The combination of TLX101 and external beam radiation is currently being studied in a Phase I/II clinical trial called IPAX-1. The trial is being conducted at several hospital locations across Europe and Australia.



About TLX101-CDx (18F-FET)

Fluoroethyl-l-tyrosine or 18F-FET has been widely used in clinical research settings while recently, new practice guidelines have been developed for the imaging of gliomas using PET with radiolabelled amino acids, of which 18F-FET is a key enabling radiopharmaceutical. TLX101-CDx (18F-FET) targets the amino acid transport system L (LAT) and is therefore highly suitable for use as a complementary diagnostic agent to TLX101.


  • Baum RP, Kluge A, Gildehaus FJ, et al. Systemic endoradiotherapy with carrier-added 4-[131I]iodo- L- phenylalanine: Clinical proof-of-principle in refractory glioma. Nucl Med Mol Imaging 2011; 45: 299–307.
  • Verburg, F.A., Sweeney, R., Hänscheid, H., Dießl, S., Israel, I., Löhr, M. et al. Patients with recurrent glioblastoma multiforme. Initial experience with p-[131I]iodo-L-phenylalanine and external beam radiation therapy. Nuklearmedizin, 2013, 52(1): 36-42.
  • Jager, P.L., Vaalburg, W., Pruim, J., de Vries, E.G., Langen, K.J., Piers, D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001, 42(3): 432-45.

With the exception of Telix’s 68Ga PSMA-11 imaging agent in Australia and the United States, none of Telix’s products have received a marketing authorisation in any jurisdiction. Any use of Telix products is on an investigational basis only.